Suda Pharmaceuticals

AU: SUD

Market CapAU$22.1m

Last Close AU$0.05

SUDA Pharmaceuticals is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system. It has the rights to ZolpiMist, the spray version of Ambien for insomnia, outside of North America.

More Suda Pharmaceuticals content >

Investment summary

SUDA Pharmaceuticals is a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system. Its most advanced product is ZolpiMist, an oro-mucosal spray version of Ambien for the treatment of insomnia that is partnered in certain regions with Teva and STADA Pharmaceuticals Australia. SUDA recently in-licensed an invariant natural killer T (iNKT) cell therapy platform that can be used in conjunction with chimeric antigen receptors to target blood cancers. There are a number of potential benefits of CAR-iNKT, including the prospect of being an allogeneic ‘off-the-shelf’ therapy, significantly simplifying the manufacture of the therapy and its delivery to patients. The therapy is currently preclinical and could be transformative for the company.

Y/E Jun
Revenue (A$m)
EBITDA (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2019A 1.2 (1.9) (2.4) (1.54) N/A N/A
2020A 0.5 (4.1) (4.7) (2.81) N/A N/A
2021E 0.5 (3.6) (4.3) (1.29) N/A N/A
2022E 1.0 (5.9) (6.6) (1.37) N/A N/A
Industry outlook

SUDA is targeting very large markets including insomnia (through ZolpiMist) and various cancers (through the CAR-iNKT programme as well as anagrelide).

Last updated on 06/10/2021
Content on Suda Pharmaceuticals
SUDA Pharmaceuticals – Half-year update
Healthcare | Update | 11 March 2021
pexels-photo-4021779
Suda Pharmaceuticals – A TGA approval and a capital raise
Healthcare | Update | 3 September 2020
pexels-photo-4021779
View more
Register to receive research on Suda Pharmaceuticals as it is published
Share price graph
Balance sheet
Forecast net cash (A$m) 6.7
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (16.4) (29.2) 12.2
Relative* (15.0) (29.1) (6.0)
52-week high/low A$0.1/A$0.0
*% relative to local index
Key management
Michael Baker CEO and Managing Director